Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SOUTH SAN FRANCISCO, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
First Data Presentation from MyoKardia-Sponsored SHaRe Patient Registry Company Co-Founder to Deliver Prestigious Distinguished Scientist Lecture SOUTH SAN FRANCISCO, Calif., Nov. 4, 2015 (GLOBE...
-
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) today announced the closing of its initial public offering of 6,253,125 shares of common stock at a public...